ArticleAdvanced healthcare materials2026
Xeno-Free Biocompatible Peptide-Based Bioinks Reinforced with Cellulose Nanofibers for 3D Printing.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Peptide-Based Nanogels for Pharmaceutical and Biotechnological Applications: From Fmoc-FF to Other Peptide Sequences.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Role of cellulose and its derivatives for 3D printing of bone tissue scaffolds.Frontiers in bioengineering and biotechnology · 2026Review
- Recent advances in multimodal foundation model-enabled peptide screening and optimization for smart biomaterials and functional tissue engineering.Frontiers in bioengineering and biotechnology · 2026Review
- Xeno-Free Biocompatible Peptide-Based Bioinks Reinforced with Cellulose Nanofibers for 3D Printing.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Tissue regeneration is a complex biological process with limited self-repair capacity, necessitating engineered solutions to restore both mechanical integrity and biological functionality. In tissue engineering and regenerative medicine, 3D printing has emerged as a promising tool for fabricating scaffolds that mimic the natural extracellular matrix (ECM). However, many bioinks are derived from animal sources, posing risks of pathogen contamination and immune responses. Additionally, many bioinks require chemical cross-linking to achieve mechanical stability, which can leave toxic residues and compromise cell viability. To address these challenges, a fully xeno-free and mechanically stable bioink is developed based on self-assembled peptides and cellulose nanofibers. The bioink combines 9-Fluorenylmethoxycarbonyl diphenylalanine (Fmoc-FF) and its ethylene glycol-conjugated derivative with a biodegradable fibrillar network of cellulose nanofibers, forming a non-cross-linked 3D scaffold. This formulation closely mimics the ECM, as confirmed by high-resolution microscopy, and supports over 95% cell viability, demonstrating exceptional biocompatibility. This work presents a novel xeno-free bioink with self-assembly and self-supporting properties, enabling reproducible 3D printing for advanced biomedical applications, including bone regeneration and personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.